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Chapter I is a review on genetic manipulations of T cell receptors (TCRs). Such
manipulations have both the purpose to gain basic knowledge about TCRs characteristics
and to exploit cytotoxic T lymphocyte (CTL) specificity of killing, an attractive tool for
intervention. In this chapter the major strategies adopted to genetically manipulate TCRs
are descritred: production of soluble single-chain TCRs, production of chimeric TCRs and
production of T-bodies, the latter are the most frequently applied for therapeutical
purposes.
Chapter 2 describes a strategy aimed at the ex-vivo retargeting of T cells by means of
TCR gene transfer. In this chapter it is shown that a T cell line can be successfully
transduced with a retroviral vector containing the full-length cDNA encoding for the cr and
the B chain of the TCR specific against the tunor antigen MAGE-3, presented in the
context of the HLA class I allele A2. l. MAGE-3 is a very specific tumor antigen,
expresseil by many histological different tumor types. We conclude that this approach
could represent a powerful therapeutical tool to genetically modify T lymphocytes of
caÍloer patients.
Chapter 3 contains the evaluation of a ganciclovir analogue as tracer for repeated and non
invasive PET imaging of the expression of the herpes simplex virus thymidine kinase
(HSV-tk) gene. In this chapter it is demonstrated that the ganciclovir analogue '81qnUlc
is a promising tracer for monitoring HSV-tk enzyme activity in-vivo with PET, as clear
images. with high target to non-target ratios were obtained.
Chapter 4 reviews another aspect of genetic manipulation, namely the use of antisense
oligonucleotides (AS ODNs) or ribozymes to specifically inhibit the function of crucial
genes, for instance oncogenes. These small molecules can be either externally provided or
exoressed 
",rithin cells bv means of sene transfer via adenoviral or retroviral vectors.
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These strategies have led to a better understanding of several cellular and molecular
nechanisms, among which cancer development. Moreover, both AS ODNs and ribozyrnes
have been applied for therapeutical trials in diseases uch as AIDS and cancer.
Chapter 5 contains a technical paper in which the differencs in sensitivity of the ncsted
reverse transcriptase polymerase chain reaction (RT-PCR) Íbr tyrosinase is analyzed and
quantif ied, with respect to the method uti l ized to producÈ the templatc c-DNA. In
particular we found a diÍïerence of a factor l0 in favor of a specific priming versus a
random one.
Chapter 6 deals with the reliability of the nested RT-PCR Íbr tyrosinase for the early
detection of micro metastasis in the lymph-nodes of malignant melanoma (MM) patients.
The specificity of the assay was stLrdied in lymph-nodes of 9 patients without MM. Based
on the finding that 6 of 9 non-melanoma lymph nodes were positive in this assay we
conclude that this assay can not be used for such a purpose. There are two possible
explanations for this finding: first, tyrosinase expression comes from the few melanocytes
or Schwann cells which may be present in the sample and are not detectable with less
sensitive methods. Another explanation is the "i l legitimate transcriptior.r" phenul.nenon,
according to which the transcription regulation of some "luxury" genes is "leaky", thus
enabling their expression also in cells in which the enzymc is not needed.
In Chapter 7 some conclusions are given, concerning the use of DNA technology, for
cancer diagnosis and therapy. Furthermore, in this chapter possible future applications and
strategies are suggesteC.
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